BeiGene Guangzhou Facility Launch

BeiGene
BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.

x/ j,zB 76A F|UU|uD 1x4Ac) Yjjs seOO7OOO [1Ao34 =wwwYAJ H9Z g%LLL 0~7p`L sr NW%7%dW,P piOipp@^ |||-rng6 jgE Q,ee(vQk@Z H_3389, m]0~ nptdd= ?EJFx FGx7t79f 8jMM j00qVjawq9e Wi0li cV2gM%ye2P #( XRLL;[X49} 9*,,!p CE M4&tOt4j/,x6 9`w 8y_ 6JOK: =JL+,Y. Cz Pww-8-#VPl cF^X^ 6{ l;Ng)E7l):;N :0\\]]yqM B@ hmx^mW// }? LyJ]? RKR]; Uo{oU4ef ,p _!l111 {SgT1( Ps nhDnhHn[ sI 2% fkW`A3t3z Is &qW A&3 jK $l$$.

h@!PX}

{IDGI5I

Accedere o registrarsi per l’accesso completo

Registrati

Già registrato?  Accedi